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Abstract
Summary Analyses of healthcare data from 30 million indi-
viduals in three countries showed that current use of
bisphosphonates may be associatedwith a small increased risk
of cardiac valvulopathy (vs. those not exposed within the pre-
vious year), although confounding cannot be entirely ruled
out. The observed tendency for decreased valvulopathy risk
with cumulative duration of bisphosphonate use >6 months
may even indicate a protective effect with prolonged use. Fur-
ther studies are st i l l needed to evaluate whether
bisphosphonates increase or decrease the risk of valvulopathy.
Introduction A signal of cardiac valve disorders with use
of bisphosphonates was identified in the literature and
EudraVigilance database, which contains reports of
suspected adverse drug reactions from worldwide
sources. The aim of this study was to evaluate the asso-
ciation using population-based healthcare data.
Methods This was a case-control study among users of
bisphosphonates and other drugs for osteoporosis in six
healthcare databases covering over 30 million individuals
in Italy, Netherlands and the UK from 1996 to 2012.
Prescriptions/dispensations were used to assess drug ex-
posure. Newly diagnosed cases of cardiac valvulopathy
were identified via disease codes/free-text search. Con-
trols were matched to each case by age, sex, database
and index date. Adjusted odds ratios (ORs) were estimat-
ed using conditional logistic regression for the pooled
data and meta-analysis of individual database risk
estimates.
Results A small but statistically significant association
was found between exposure to bisphosphonates as a
class and risk of valvulopathy. Overall risk was 18 %
higher (95 % CI 12–23 %) in those currently exposed
to any bisphosphonate (mainly alendronate and
risedronate) vs. those not exposed within the previous
year. Risk of valve regurgitation was 14 % higher
(95 % CI 7–22 %). Decreased valvulopathy risk was
observed with longer cumulative duration of bisphospho-
nate use, compared to use of less than 6 months. Meta-
analyses of database-specific estimates confirmed results
from pooled analyses.
Conclusions The observed increased risks of cardiac
valvulopathy with bisphosphonate use, although statisti-
cally significant, were quite small and unlikely to be clin-
ically significant. Further studies are still needed to eval-
uate whether bisphosphonates increase or decrease the
risk of valvulopathy and to investigate possible mecha-
nisms for the association.
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Introduction
Bisphosphonates are drugs widely used in the treatment and
prevention of bone‐related disorders including osteoporosis,
Paget’s disease and complications related to metastatic bone
cancer and multiple myeloma [1–3]. A signal of cardiac valve
calcification leading to valve incompetence associated with
exposure to bisphosphonates was found in the post‐authorisa-
tion analysis of EudraVigilance (http://eudravigilance.ema.
europa.eu), which contains spontaneous reports of suspected
adverse drug reactions from Europe and the rest of the world.
This statistical signal of disproportionate reporting was
associated with four products of the class (alendronate,
ibandronate, pamidronate and zoledronate) [4]. The signal
was supported by an earlier study conducted within the
Multi-Ethnic Study of Atherosclerosis (MESA) cohort which
showed that prevalence of aortic valve (AV) and vascular cal-
cification was higher among female users of bisphosphonates
compared to non-users [5].
Valvulopathy is responsible for an increasing propor-
tion of cardiovascular surgical interventions, especially in
the setting of an aging population in the USA and Europe,
where age-related valve degeneration is the prevailing
cause [6]. Drug exposure has been recognised as a cause
of valvulopathy since the 1960s when methysergide and
ergotamine were found to induce valve regurgitation
[7–9]. Other drugs implicated later were fenfluramine
and dexfenfluramine [10–12], pergolide and cabergoline
[13–15] and most recently benfluorex [16, 17].
Most of the literature on bisphosphonates and cardiovascu-
lar outcomes has investigated the possible role of
bisphosphonates in reducing cardiac calcification and athero-
sclerotic burden [18, 19] and in delaying progression of AV
stenosis [20]. However, concerns have been recently raised
regarding cardiovascular safety of bisphosphonates (several
studies reporting inconsistent associations with atrial fibrilla-
tion and heart failure) [21–23]. The aim of this study was to
determine the risk of newly diagnosed cardiac valvulopathy,
including valve regurgitation and calcification, among users
of bisphosphonates.
Methodology
Data sources
This study used data from six population-based healthcare
databases from three countries during the period 1996–2012:
(1) Health Search Database (HSD, Italy), (2) Integrated Pri-
mary Care Information (IPCI, Netherlands), (3) The Health
Improvement Network (THIN, UK), (4) PHARMO (Nether-
lands), (5) Lombardy (Italy) and (6) Tuscany (Italy). HSD,
IPCI and THIN are general practitioner (GP) databases where
clinical information including consultations and diagnoses,
referrals to secondary care/hospitalisations and drug prescrip-
tions are recorded. PHARMO and the regional databases of
Tuscany and Lombardy are record-linkage administrative
(claims) systems where drug dispensations are linked to reg-
istries containing hospitalisations and other services. A more
detailed description of the databases can be found in earlier
publications [24–31]. Standardised software (Jerboa©) was
used to extract and pool data using a distributed network
[24]. The respective Scientific and Ethics committees of each
database approved this study. Key characteristics of the data-
bases are summarised in Table S1 (Appendix, available as
supplementary material online).
Study design
This was a case-control study nested in a cohort of new users
of bisphosphonates (primary cohort). A secondary assessment
was conducted by performing similar analyses in a cohort of
users of bisphosphonates and other drugs used in treatment of
osteoporosis (extended cohort). All individuals registered in
the databases who had at least 1 year of valid medical history
were eligible for study entry. Eligibility ended with de-regis-
tration, death or end of study period. From all eligible subjects,
the primary cohort was defined as all patients receiving first
prescription/dispensation of any bisphosphonate after start of
eligibility period. The extended cohort comprised all patients
who received any prescription/dispensation of bisphospho-
nate as well as any other drug used in osteoporosis treatment
(i.e. strontium ranelate, denosumab, teriparatide, raloxifene,
calcitonin, parathyroid hormone, vitamin D/calcium
preparations).
All subjects who received (at any time prior to or during the
study period) prescription of a drug known to potentially
cause cardiac valve fibrosis (i.e. pergolide, cabergoline, ami-
odarone, fenfluramine, dexfenfluramine, phentermine,
benfluorex) were excluded, as were patients with history of
valvulopathy, endocarditis, valve replacement, carcinoid syn-
drome or acromegaly.
Case identification
All newly diagnosed cases of valvulopathy were identified
using disease codes extracted from hospital discharge diagno-
ses (claims databases) and primary care physician-recorded
diagnoses (GP databases). In addition, free-text search of un-
structured clinical narratives was performed in GP databases.
Diagnostic codes (Table S2, supplementary material) were
harmonised from the following disease terminologies: (1) In-
ternational Classification of Primary Care (ICPC)—IPCI; (2)
International Classification of Diseases, 9th revision-Clinical
Modification (ICD-9CM)—Lombardy, Tuscany, HSD,
PHARMO; and (3) Read code classification—THIN. Valve
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regurgitation and valve calcification were investigated sepa-
rately. Only HSD, IPCI and THIN provided data on valve
calcification as no specific code exists in ICD9-CM or ICPC;
the outcome was identified with free-text search in HSD and
IPCI and with Read code (code specific for AV calcification
only) in THIN. Validation of a random sample of cases
through manual review of medical records was conducted in
IPCI and HSD to verify that diagnoses were confirmed by a
cardiologist and/or by evidence from echocardiography or
other procedure. Incidence rates of outcomes were calculated
overall and per database, age-standardised according to the
World Health Organisation Standard Population.
Controls (matched by age, sex and database) were
selected from each cohort by incidence density sampling.
In each case-control set, index date was defined as date
of diagnosis of the case.
Exposure assessment
Prescriptions/dispensations were used to assess drug expo-
sure. Duration covered by each prescription/dispensation
was estimated according to legend duration (if dosing regimen
is available) or otherwise based on defined daily dose [32]. In
line with previous publications that investigated drug-induced
valvulopathy using observational databases, a carry-over pe-
riod of 180 days was included for each prescription to account
for induction time and possible delay in recording of the event
after initial clinical manifestations [14, 15]. The following
exposure categories were defined: (1) current use, referring
to prescription duration that lasts up to index date or ends
≤180 days before; (2) past use, i.e. duration of prescription
ending between 180 and 365 days before index date; and (3)
distant past, i.e. no exposure within 365 days before index
date.
Statistical analyses
Different case-control sets were generated for each of the
three outcomes. Using conditional logistic regression,
odds ratios (ORs) and 95 % confidence intervals (95 %
CIs), with ‘distant past use’ as reference, were estimated
for current and past use of bisphosphonates as a class
and of individual bisphosphonates. The following co-
morbidities were considered as potential confounders:
heart failure, hypertension, arrhythmias, coronary heart
disease, cerebrovascular disorders, peripheral arterial dis-
ease, venous thromboembolism, obesity, autoimmune
disorders, chronic obstructive pulmonary disease, chronic
renal failure and diabetes mellitus. Prior use of lipid-
lowering drugs and of gastroprotective agents was also
taken into account. Only those confounders associated (p
value <0.10) with the outcome in a univariate analysis
were subsequently entered in the final model and
selected using backward selection. ORs were likewise
estimated for use of other anti-osteoporosis drugs, as
previously described. Analyses were performed for each
database separately and for the (unweighted) pooled data.
Meta-analyses (random and fixed effects) of single data-
base results were done. Heterogeneity was evaluated
using Cochran’s Q statistic. All statistical analyses were
done using SAS version 9.2 (SAS Institute Inc., Cary,
NC).
Additional analyses were conducted to determine whether
age (≥ or <65 years) and sex are effect modifiers of the asso-
ciation between valvulopathy and bisphosphonates. Effects of
duration of treatment and switching from bisphosphonate to
other anti-osteoporosis drug (and vice versa) were also evalu-
ated. Effect of dosage could not be assessed, as this informa-
tion was not consistently available across the databases.
Sensitivity analyses
Post-hoc sensitivity analyses were conducted to investigate
the impact of residual confounding on the observed associa-
tion. Both the array approach and rule-out approach, as rec-
ommended by Schneeweiss, were used. Using the array ap-
proach, we considered severity of osteoporosis as an unmea-
sured confounder, assuming a (fixed) 10 % prevalence of se-
vere osteoporosis among distant past users of any bisphospho-
nate and varying the prevalence among current users between
0 and 50 %. Using the rule-out approach, considering all pos-
sible unmeasured confounders (which may include smoking
and over-the-counter use of calcium supplements) as a single
factor, we looked at how strong unmeasured confounding has
to be in order to explain observed association, assuming prev-
alence of the confounder to be 20 %.
Results
The overall study population comprised 30,332,837 individ-
uals with 225,027,048 person-years of follow-up. The primary
study cohort included 872,872 new users of bisphosphonates
while the extended cohort included 1,597,135 users of any
drug for os teoporos is . Most of the exposure to
bisphosphonates was accounted for by alendronate (55 %)
and risedronate (24%),with an average exposure of 12months
per patient. There were 234,285 cases of valvulopathy overall
(independent of any drug exposure), with age-standardised
incidence rate of 95.4/100,000 person-years. Corresponding
background incidence rates of valve regurgitation and valve
calcification were 51.9/100,000 person-years and 1.4/100,
000 person-years, respectively.
Within the primary cohort, a total of 8757 cases of
valvulopathy were identified. There were 4914 cases (56 %)
of valve regurgitation and 57 cases (1.2 %) of valve
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calcification. Table 1 shows the characteristics of cases and
their matched controls for each outcome separately. Majority
were female and between 65 and 80 years of age. Cases had a
higher prevalence of several co-morbidities, including cardio-
vascular co-morbidities, compared to matched controls.
Within the extended cohort, 17,362 cases of valvulopathy
were identified, including 9544 cases (55 %) of valve regur-
gitation and 144 cases (0.8 %) of valve calcification. In gen-
eral, the characteristics of cases in extended cohort were sim-
ilar to those of the primary cohort (Table 1). All ORs reported
below are adjusted; crude ORs are specified in the tables.
Risk of valvulopathy among new bisphosphonate users
Patients with valvulopathy were predominantly current users
of any bisphosphonate (61 %) (see Table 2). Pooled analyses
showed a very small, although statistically significant, in-
creased risk of valvulopathy with both current (OR 1.18,
95 % CI 1.12–1.23) and past use of any bisphosphonate
(OR 1.11, 95 % CI 1.03–1.21), when compared to distant past
use (i.e. no bisphosphonate use in the previous year).
Alendronate (36.3 % of current users) and risedronate
(14.4 %) together accounted for the largest exposure to
bisphosphonates among cases. After adjusting for relevant
covariates, increased risk of valvulopathy was observed with
current use of alendronate (OR 1.19, 95 % CI 1.12–1.25) and
with current use of risedronate (OR 1.20, 95 % CI 1.12–1.28).
No increased risk was observed for any other individual bis-
phosphonate, except for the fixed combination of alendronate/
cholecalciferol: OR 1.18 (95 % CI 1.07–1.31).
The adjusted ORs observed per database and results of
meta-analyses are shown in Fig. 1. A slightly increased
valvulopathy risk with current use of any bisphosphonate
was found in all databases (except IPCI, which reported a
wide 95 % CI due to a low number of exposed cases), and
meta-analysis confirmed this small increased risk: random-
effects OR 1.19 (95 % CI 1.11–1.28). A similarly small in-
creased risk with current use of ≥1 bisphosphonate was ob-
served in the Lombardy database; however, because of
Lombardy’s large data contribution to the entire database net-
work (42 %), meta-analysis retained the increased risk: OR
1.31 (95 % CI 1.11–1.54). Meta-analyses likewise confirmed
increased risk with current use of alendronate, risedronate and
alendronate/cholecalciferol.
Risk of valve regurgitation among new bisphosphonate
users
As shown in Table 2, exposure pattern of patients with valve
regurgitation was similar to that of valvulopathy overall. Es-
timates from pooled analyses show that both current use (OR
1.14, 95 % CI 1.07–1.22) and past use (OR 1.21, 95 % CI
1.09–1.35) of any bisphosphonate were associated with a
slightly increased risk of valve regurgitation. Specifically, cur-
rent use of alendronate (OR 1.15, 95 % CI 1.07–1.24),
risedronate (OR 1.18, 95 % CI 1.07–1.29) and alendronate/
cholecalciferol (OR 1.16, 95 % CI 1.01–1.33) was associated
with this small increased risk. Figure 2 shows the database-
specific and meta-analysis estimates for valve regurgitation.
Risk of valve calcification among new bisphosphonate
users
Neither current nor past use of bisphosphonates—either indi-
vidually or as a class—was significantly associated with risk
of valve calcification (Table 1) in any of the three databases
that provided data for this outcome.
Risk of valvulopathy among users of drugs
for osteoporosis
Secondary analyses looking at valvulopathy risk among users
of all osteoporosis drugs resulted in risk estimates consistent
with those derived from the primary analysis. Both pooled and
meta-analyses showed increased valvulopathy risk with cur-
rent use of any bisphosphonate and with past use of any oste-
oporosis drug, when compared with distant past use of any
drug (see summary in Appendix, available as supplementary
material online).
Effects of switching and duration of use
As shown in Table 3, valvulopathy risk appears to be lower
when bisphosphonates are used for ≥6 months compared to
<6 months. Switching from bisphosphonate to non-bisphos-
phonate, or switching from non-bisphosphonate to bisphos-
phonate, did not significantly increase risk of valvulopathy
when compared to non-bisphosphonate alone. Neither age
(<65 vs. ≥65) nor sex modified the risk of valvulopathy
among bisphosphonate users (Table S4, supplementary
material).
Sensitivity analyses
As shown in Figure S3 (Appendix, available as supplementary
material online), as the imbalance (between those currently
exposed to bisphosphonates vs. those not exposed within the
previous year) of the unmeasured confounder increases, the
adjusted relative risk moves closer to 1 and even further below
1 (0.6).
The curve shown in Figure S4 (Appendix, available as
supplementary material online) denotes the various combina-
tions of strength of association of the unmeasured confounder
with valvulopathy and with bisphosphonate use that are re-
quired to bring down the observed OR of 1.18 to null. The
unknown confounding would have to increase the relative
1862 Osteoporos Int (2016) 27:1857–1867
odds of valvulopathy by a factor of 2.5 and simultaneously
increase the odds of bisphosphonate exposure by a factor of
4.2 in order for adjustment to completely remove the observed
association.
Discussion
This study combined data from six population-based healthcare
databases in three countries (source population >30 million
individuals) to investigate the relationship between use of
bisphosphonates and cardiac valvulopathy. The overall risk of
(non-rheumatic) valvulopathy was found to slightly increase—
by 18 %—among current users of bisphosphonates compared
to those who discontinued bisphosphonate therapy (or had no
bisphosphonate exposure at all) longer than 1 year prior. Risk
of valve regurgitation specifically increased by 14 % among
current users. These estimates were based on analysis of pooled
data and meta-analytic pooling of database-specific estimates.
Among individual bisphosphonates, alendronate, alendronate/
cholecalciferol and risedronate were associated with increased
risk, which was observed not only among new bisphosphonate
users but also among users of any drug for osteoporosis. These
increased risks were similar between those ≥65 years and those
Fig. 1 Risk of cardiac valvulopathy among new users of
bisphosphonates, results of meta-analyses (all ORs are adjusted for
relevant confounders). a Current use of any bisphosphonate (test for
heterogeneity: Q statistic=8.489; p value=0.1313; I2=41.1). b Past use
of any bisphosphonate (test for heterogeneity: Q statistic=3.3874; p
value=0.6405; I2=0). c Current use of >1 bisphosphonate (test for
heterogeneity: Q statistic=5.0599; p value=0.4086; I2=1.18). d
Current use of alendronate (test for heterogeneity: Q statistic=7.6714; p
value=0.1753; I2=34.82). e Current use of risedronate (test for
heterogeneity: Q statistic=4.4672; p value=0.4843; I2=0). f Current
use of alendronate/cholecalciferol (test for heterogeneity: Q statistic=
10.603; p value=0.0314; I2=62.27. LCL95 lower limit of 95 %
confidence interval, UCL95 upper limit of 95 % confidence interval,
ARS Tuscany regional database, HSD Health Search database, IPC IPCI
database, LOM Lombardy regional database, PHA PHARMO database,
THI THIN database, Fix fixed-effect meta-analysis, Ran random-effects
meta-analysis
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who are younger as well as in both sexes. Duration of bisphos-
phonate use did not change the association, although there was
a tendency of lower risk with longer use (>6 months).
Switching from bisphosphonate to a non-bisphosphonate (or
vice versa) within 180 days before index date did not change
risk of valvulopathy.
The observed increased risks, although statistically signif-
icant, were quite small and are unlikely to be clinically signif-
icant. No biological mechanism accounting for the association
of bisphosphonates with cardiac valvulopathy could be iden-
tified. The predominant pathology that has been described in
drug-induced valvulopathy involves proliferative and fibrotic
tissue changes, the mechanism being largely attributed to ac-
tion of serotonin which promotes fibroblast and smooth
muscle cell proliferation via upregulation of target proteins
including G protein and transforming growth factor beta [33,
34]. All drugs known to induce valvulopathy (or their metab-
olites, in the case of fenfluramine and benfluorex) have been
demonstrated to be agonists of the specific serotonin receptor
5HT2B, which abound in valvular tissue [35]. The
bisphosphonates are not known to act as substrate for this
receptor, however; neither are bisphosphonates structurally
similar to ergot-derived dopamine agonists or amphetamine-
like anorexiants. The cross-sectional MESA study [5] found
higher prevalence of AV and vascular calcification among
bisphosphonate users compared to non-users, although no po-
tential mechanisms that could explain this observation were
proposed (prevalence of calcification of aortic valve ring and
Fig. 2 Risk of cardiac valve regurgitation among new users of
bisphosphonates, results of meta-analyses (all ORs are adjusted for
relevant confounders). Current use of any bisphosphonate (test for
heterogeneity: Q statistic=11.2028; p value=0.0475; I2=55.37). a Past
use of any bisphosphonate (test for heterogeneity: Q statistic=2.8689; p
value=0.7202; I2=0). b Current use of >1 bisphosphonate (test for
heterogeneity: Q statistic=6.7041; p value=0.2436; I2=25.42). c
Current use of alendronate (test for heterogeneity: Q statistic=7.7652; p
value=0.1697; I2=35.61). d Current use of risedronate (test for
heterogeneity: Q statistic=11.562; p value=0.04131; I2=56.76). e Cur-
rent use of etidronate/calcium (test for heterogeneity: Q statistic=
3.3754; p value=0.1850; I2=40.75). LCL95 lower limit of 95 %
confidence interval, UCL95 upper limit of 95 % confidence interval,
ARS Tuscany regional database, HSD Health Search database, IPC IPCI
database, LOM Lombardy regional database, PHA PHARMO database,
THI THIN database, Fix fixed-effect meta-analysis, Ran random-effects
meta-analysis
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mitral annulus was similar in users and non-users). Moreover,
in this study, the prevalence of calcification overall among
bisphosphonate users was higher in women <65 years com-
pared to those older [5].
Valve calcification is associated with upregulation of mor-
phogenetic proteins, a process similar to bone formation, and
has been shown to be integral to disease onset and progression
in histopathologic studies of AV stenosis, which itself be-
comes more prevalent with the aging population [36]. Earlier
studies have hypothesised that bisphosphonates actually have
the opposite effect: inhibition of vascular calcification and
slowing of progression of aortic stenosis. This effect is attrib-
uted to bisphosphonates’ inhibition of farnesyl pyrophosphate
synthase, a key enzyme in the mevalonate pathway affecting
both protein prenylation and cholesterol biosynthesis; inhibi-
tion of the mevalonate pathway leads to tissue effects similar
to those seen with statin therapy [37]. Moreover,
bisphosphonates prevent bone resorption and slow the release
of calcium phosphate particles from the bone, which possibly
retard the deposition of calcium in vascular and valvular tis-
sues. The number of cases of valve calcification identified in
this current study was too low to enable useful inference, but
the observed tendency for decreased valvulopathy risk with
longer duration of bisphosphonate use in this study may actu-
ally indicate a protective effect with prolonged use, supporting
findings in previous studies that bisphosphonates reduce car-
diac calcification and delay progression of valve stenosis.
Such protection may reflect reduced vascular calcification
with more prolonged inhibition of the mevalonate pathway;
further studies are necessary to investigate this, including the
effect of dose and dosing intervals.
As this study was observational, there are several limita-
tions. Misclassification of the outcome may have occurred,
although validation by review of medical records was done
in some databases to limit the effects of possible misclassifi-
cation. Individual echocardiographic reports were not system-
atically reviewed since such information was not consistently
available across all databases. Very early stages of the disease,
during which a patient is asymptomatic, may not have re-
ceived medical attention and thus not documented in the
healthcare records. Prescriptions/dispensations were consid-
ered as proxy for actual drug consumption, which may not
always be a reliable assumption, particularly because adher-
ence to bisphosphonate therapy remains notoriously poor [38,
39]. Information bias from potential misclassification of the
outcome and exposure may have resulted in an underestima-
tion of the effect, as it is unlikely to be differential. More
importantly, a paradoxical calcification has been described
among those with reduced bone density or increased bone
turnover, suggesting that osteoporosis (the indication for tak-
ing bisphosphonates) itself may account for the observed as-
sociation [40, 41]. The finding that switching from bisphos-
phonate to non-bisphosphonate (and vice versa) does notTa
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significantly increase the risk of valvulopathy, when com-
pared to non-bisphosphonate alone, also reinforces the
possible confounding by osteoporosis. Berksonian bias
could be another possible explanation for the observed
association: patients who use bisphosphonates (for osteoporo-
sis or other condition, such as malignancy) are often elderly
and have other co-morbidities and are thus more likely to be
subjected to more extensive clinical monitoring and investi-
gation, increasing the likelihood of detecting cardiac valve
disorders (that may be asymptomatic). Reliable data on
smoking and severity of osteoporosis (as well as use of over-
the-counter calcium supplements) were not available and thus
were not adjusted for in the analyses. Although residual con-
founding cannot be entirely ruled out, the sensitivity analyses
conducted indicate that unknown confounding would need to
have relatively strong associations with the outcome and ex-
posure to explain the observed association (smoking, for ex-
ample, has been shown to increase the risk of valvulopathy by
no more than 2).
In conclusion, while this study among users of drugs
for osteoporosis in three countries showed that current
use of bisphosphonates (mainly alendronate and
risedronate) may be associated with a small increased
risk of cardiac valvulopathy, the risk is unlikely to be
clinically significant. The observed tendency for de-
creased valvulopathy risk with duration of bisphospho-
nate use greater than 6 months could even indicate a
protective effect with prolonged use. Further studies are
still needed to evaluate whether bisphosphonates increase
or decrease the risk of cardiac valvulopathy and to in-
vestigate possible mechanisms for the association.
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